Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- Volatility is at a recent 2 week low. A recent low volatility of stock movement within a box range could trigger break through when activities pick up.
- A moving average of short volume ratio is at a recent 2 week low. A lower short volume ratio could be a bullish signal.
| MarketCap | 823.4M |
|---|---|
| PE Ratio | 20.5 |
| PEG Ratio | 27.1 |
| P/B | 4.5 |
| P/S (ttm) | 2.4 |
| Earning Growth (QoQ) | 3380% |
| Revenue Growth (QoQ) | |
| Short % | 17% |
| Held by Institutions % | 111% |
| 1 Day Vol Adjusted Return | 0.5 |
| 1 Month Vol Adjusted Return | 2.8 |
| 3 Month Vol Adjusted Return | -3.5 |
| 6 Month Vol Adjusted Return | 10.0 |
| 20 Days SMA Price ZScore | 0.2 |
| 50 Days SMA Price ZScore | 0.5 |
| 12 -26 Days PPO | -0.2 |
| 1 Month Average Short Volume Ratio | 54.8 |
| 1 Day Volume Change ZScore | -1.5 |
| 1 Month Daily Vol | 2.5 |
Stock news
The White House's plans to address the U.S. opioid crisis could be good news for Heron Therapeutics and Collegium Pharmaceutical, makers of safer pain management drugs.
STOUGHTON, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conference: Jefferies Virtual Healthcare Conference Format: Fireside chat Date: Wednesday, June 2, 2021Time: 4:30 PM Eastern Time The presentation will be webcast live and may be accessed from the Investor section of the Company’s...
COLL earnings call for the period ending March 31, 2021.
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 36.67% and 8.01%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
– Net Income of $15.7 Million and Adjusted EBITDA of $45.3 Million in the First Quarter of 2021 – – Nucynta® Franchise and Adjusted EBITDA 2021 Guidance Range Raised – – Colleen Tupper Appointed as Next CFO; Paul Brannelly will be Leaving the Company to Pursue Other Opportunities – – Conference Call Scheduled for Today at 4:30 p.m. ET – STOUGHTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leade...
NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Collegium Pharmaceutical, Inc. (NASDAQ:COLL) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 6, 2021 at 4:30 PM Eastern Time.
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Better yet, you'd...